Survival outcomes in patients with stages I–III gastric adenocarcinoma treated with surgery alone versus surgery plus adjuvant chemotherapy: A systematic review
Journal of Biological Methods · 18.04.2025 · 12 (2) · e99010060
DOI: 10.14440/jbm.2025.0135 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biological Methods, online erschienen am 18.04.2025. Verfasst von Naveena Kaur Rikhraj. Beteiligte Einrichtung: Department of Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Lancashire PR2 9HT, United Kingdom. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Gastric adenocarcinoma, the malignant proliferation of glandular cells in stomach epithelium, is a type of gastric cancer with a statistical disease burden of the fifth most common cancer globally and the 17th most common malignancy in the United Kingdom. Prognosis varies with stage (I–IV), with stages I–III showing promising 5-year survival rates up to 71.8%, warranting timely diagnosis and treatment. Surgery is the gold-standard treatment; however, due to complex tumor pathophysiology, there is growing interest in the use of multimodal therapies. Specifically, the combination of surgery and adjuvant chemotherapy has become a key focus of the treatment for stages I–III gastric adenocarcinoma.
Objective
The study reviewed patients with stages I–III (non-advanced) gastric adenocarcinoma to assess whether adjuvant chemotherapy combined with surgery provides better disease-free/disease-specific/cause-specific survival, overall survival, and reduced recurrence rates/improved recurrence-free survival, compared to surgery alone. Analyzed were 17 English-language, full-text, levels I–III peer-reviewed studies from MEDLINE and Embase from the past 10 years were analyzed. No age/sex/ethnicity/country restrictions were applied, and the dimension of interest was limited to stages I–III gastric adenocarcinoma patients who underwent tumor resection through surgery and received chemotherapy as the only adjuvant therapy. Seven (41.2%) studies have more than one statistically significant outcome measure supporting the benefit of adjuvant chemotherapy in combination with surgery over surgery alone. Ten (58.8%) studies showed no statistically significant benefit of adjuvant chemotherapy.
Conclusion
The findings contrasted with previous large-scale meta-analyses, which were limited by sample size and biases in individual studies reviewed. Continued research, incorporating advances in surgical techniques and new chemotherapeutic combinations, is necessary to ascertain best-tailored treatments for gastric adenocarcinoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Lancashire PR2 9HT, United Kingdom.
- Department of Medical Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester M13 9PL, United Kingdom.
- Department of Medicine, School of Medicine, University of St Andrews, Fife, Scotland KY16 9TF, United Kingdom.
Zitieren
APA
Rikhraj, N. K. (2025). Survival outcomes in patients with stages I–III gastric adenocarcinoma treated with surgery alone versus surgery plus adjuvant chemotherapy: A systematic review. Journal of Biological Methods, 12(2), e99010060. https://doi.org/10.14440/jbm.2025.0135
Vancouver
Rikhraj NK. Survival outcomes in patients with stages I–III gastric adenocarcinoma treated with surgery alone versus surgery plus adjuvant chemotherapy: A systematic review. Journal of Biological Methods. 2025;12(2):e99010060. doi:10.14440/jbm.2025.0135
BibTeX
@article{Rikhraj2025,
author = {Rikhraj, Naveena Kaur},
title = {Survival outcomes in patients with stages I–III gastric adenocarcinoma treated with surgery alone versus surgery plus adjuvant chemotherapy: A systematic review},
journal = {Journal of Biological Methods},
year = {2025},
volume = {12},
number = {2},
pages = {e99010060},
doi = {10.14440/jbm.2025.0135}
}
EUVIMED